Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc. - Common Shares (NQ:THTX)

1.500 -0.170 (-10.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 820,809
Open 1.610
Bid (Size) 1.500 (9)
Ask (Size) 1.540 (3)
Prev. Close 1.670
Today's Range 1.500 - 1.640
52wk Range 1.080 - 2.180
Shares Outstanding 77,013,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks are being observed in Thursday's session. 
Via Chartmill
Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety

Performance

YTD
-18.5%
-18.5%
1 Month
-17.4%
-17.4%
3 Month
-18.0%
-18.0%
6 Month
+26.1%
+26.1%
1 Year
+2.7%
+2.7%

More News

Read More
Top movers in Wednesday's pre-market session
Via Chartmill
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Examining the Future: Theratechnologies's Earnings Outlook
Via Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
From Theratechnologies
Via GlobeNewswire
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Resumes Distribution of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Theratechnologies Provides Update on EGRIFTA SV® Supply
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Resumed Production of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
From Theratechnologies
Via GlobeNewswire
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
From Theratechnologies
Via GlobeNewswire
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
From Theratechnologies
Via GlobeNewswire

Frequently Asked Questions

Is Theratechnologies Inc. - Common Shares publicly traded?
Yes, Theratechnologies Inc. - Common Shares is publicly traded.
What exchange does Theratechnologies Inc. - Common Shares trade on?
Theratechnologies Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Theratechnologies Inc. - Common Shares?
The ticker symbol for Theratechnologies Inc. - Common Shares is THTX on the Nasdaq Stock Market
What is the current price of Theratechnologies Inc. - Common Shares?
The current price of Theratechnologies Inc. - Common Shares is 1.500
When was Theratechnologies Inc. - Common Shares last traded?
The last trade of Theratechnologies Inc. - Common Shares was at 03/28/25 04:00 PM ET
What is the market capitalization of Theratechnologies Inc. - Common Shares?
The market capitalization of Theratechnologies Inc. - Common Shares is 115.52M
How many shares of Theratechnologies Inc. - Common Shares are outstanding?
Theratechnologies Inc. - Common Shares has 116M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.